Novo Nordisk A/S has turned to the University of Oxford for support in developing new approaches to treat Type 2 diabetes, a disease that affects nearly 9% of the global population. While Novo has a dominant global market position in the field, it is seeking to discover new treatments for people living with the disease and its complications.
